According to the results of the early study, published simultaneously in the New England Journal of Medicine, 92% of patients ...

New research shows 92% of cancer patients stayed cancer-free for two years after immune-based therapy, potentially avoiding ...

Adding pembrolizumab (Keytruda), before and after surgery, to standard adjuvant therapy for locally advanced head and neck ...

Neoadjuvant PD-1 blockade in dMMR tumors "could potentially eradicate the need for chemotherapy, radiation, and surgery in ...

The data, presented in a poster titled "AP402, a bispecific antibody targeting p95HER2 and CD137, shows potent antitumor activity," highlight the therapeutic potential of AP402 to address ...

Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune ...

With the American Association for Cancer Research’s annual conference now underway, oncology researchers can expect ...

The AACR meeting was full of promising data on the vaccine against cervical cancer, a lung cancer drug and the next ...

Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and ...

Lyon, France-based late-stage clinical biotech MaaT Pharma has presented new preclinical data for MaaT034 at the American ...

Lyon, France-based late-stage clinical biotech MaaT Pharma has presented new preclinical data for MaaT034 at the American ...